bpc 157 regulatory status fda 2025 Alert: The Legal of BPC-157 in Compounding and Clinical Practice – Holt Law FDA Compliance for Peptide Therapy

Tornesello AL, Borrelli A, Buonaguro L, Buonaguro FM, Tornesello ML

What they found (summary): NAD+ levels decline linearly with age in all tissues Sirtuins are glucose sensors , activated during caloric restriction and fasting The decline in NAD+ leads to pseudohypoxia in aging cells Supplementation with NAD+ precursors in animal models restores sirtuin activity Therapeutic perspectives: NMN, NR, sirtuin activators, CD38 inhibitors Why it matters: This is the reference article for the entire field

Troubleshoot aggregation and precipitation early, and verify concentration with lab methods when accuracy counts

Growth Factor Modulation

Not just dihexa half life but also clearance mechanisms, bioavailability, and receptor kinetics